Biomarkers predicting oncological outcomes of high-risk non-muscle-invasive bladder cancer

Cancer statistics, 2020

(2020) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy

(2020) Ahmet Murat Aydin et al.   WORLD JOURNAL OF UROLOGY

Epidemiology and unmet needs of bladder cancer in Italy: a critical review

(2020) Cosimo De Nunzio et al.   Minerva Urologica E Nefrologica

Relationship between cellular and exosomal miRNAs targeting NOD-like receptors in bladder cancer: preliminary results

(2020) Giulia Poli et al.   Minerva Urologica E Nefrologica

Bacillus Calmette-Guérin unresponsiveness in non-muscle-invasive bladder cancer patients: what the urologists should know

(2019) Marco Moschini et al.   Minerva Urologica E Nefrologica

Evaluation of the UroVysion™ Test to Predict Recurrence and/or Progression of Disease After BCG for Primary High Grade Non-Muscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial

(2019) Yair Lotan et al.   JOURNAL OF UROLOGY

Predictive factors for progression of patients with carcinoma in situ of the bladder at long-term follow-up: pure versus non-pure CIS

(2019) Rodolfo Hurle et al.   Minerva Urologica E Nefrologica

Blocking PD-1/PD-L1 in Genitourinary Malignancies

(2018) Matthew C. Dallos et al.   CANCER JOURNAL

Molecular Progression Risk Score for Prediction of Muscle Invasion in Primary T1 High-Grade Bladder Cancer

(2018) Ho Won Kang et al.   Clinical Genitourinary Cancer

High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma

(2018) Johannes Breyer et al.   Clinical Genitourinary Cancer

Altered expression of HER-2 and the mismatch repair genes MLH1 and MSH2 predicts the outcome of T1 high-grade bladder cancer

(2018) Francesca Sanguedolce et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer

(2018) Francesco Soria et al.   WORLD JOURNAL OF UROLOGY

FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer

(2018) Johannes Breyer et al.   BJU INTERNATIONAL

Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018

(2018) Marcus George Kwesi Cumberbatch et al.   EUROPEAN UROLOGY

NCCN Guidelines Insights: Bladder Cancer, Version 5.2018

(2018) Thomas W. Flaig et al.   Journal of the National Comprehensive Cancer Network

Prediction of intravesical recurrence of non-muscle-invasive bladder cancer by evaluation of intratumoral Foxp3+ T cells in the primary transurethral resection of bladder tumor specimens

(2018) Ryosuke Murai et al.   PLoS One

Long-term outcomes of high-grade T1 bladder cancer treated with intravesical bacillus Calmette-Guérin: experience of a single center

(2018) Rodolfo Hurle et al.   Minerva Urologica E Nefrologica

Down-regulation of A-FABP predicts non-muscle invasive bladder cancer progression: investigation with a long term clinical follow-up

(2018) Christel Mathis et al.   BMC CANCER

Loss of GAS5 tumour suppressor lncRNA: an independent molecular cancer biomarker for short-term relapse and progression in bladder cancer patients

(2018) Margaritis Avgeris et al.   BRITISH JOURNAL OF CANCER

Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer

(2018) F. Johannes P. van Valenberg et al.   EUROPEAN UROLOGY

Heat shock proteins 60 and 70 are associated with long-term outcome of T1-stage high-grade urothelial tumors of the bladder treated with intravesical Bacillus Calmette-Guérin immunotherapy

(2018) Roy Mano et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer

(2017) J. Alfred Witjes et al.   EUROPEAN UROLOGY

The long-term prognostic value of survivin expressing circulating tumor cells in patients with high-risk non-muscle invasive bladder cancer (NMIBC)

(2017) Chiara Nicolazzo et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Ki-67 Contributes to Normal Cell Cycle Progression and Inactive X Heterochromatin in p21 Checkpoint-Proficient Human Cells

(2017) Xiaoming Sun et al.   MOLECULAR AND CELLULAR BIOLOGY

Characterization of inflammasome-related genes in urine sediments of patients receiving intravesical BCG therapy

(2017) Giulia Poli et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Validation of the ezrin, CK20, and Ki-67 as potential predictive markers for BCG instillation therapy of non–muscle-invasive bladder cancer

(2017) Per-Uno Malmström et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival

(2017) Johannes Breyer et al.   VIRCHOWS ARCHIV

Human epidermal growth factor receptor 2 expression is more important than Bacillus Calmette Guerin treatment in predicting the outcome of T1G3 bladder cancer

(2017) Luigi Cormio et al.   Oncotarget

Inflammasomes and Cancer

(2017) Rajendra Karki et al.   Cancer Immunology Research

T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-II α , survivin, and E-cadherin

(2016) Maria Rosaria Raspollini et al.   HUMAN PATHOLOGY

WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach

(2016) Wolfgang Otto et al.   INTERNATIONAL UROLOGY AND NEPHROLOGY

Downregulated KLK13 expression in bladder cancer highlights tumor aggressiveness and unfavorable patients’ prognosis

(2016) Theodoros Tokas et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Cyclin D1, cancer progression, and opportunities in cancer treatment

(2016) Shuo Qie et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway

(2016) Vassiliki A. Boussiotis   NEW ENGLAND JOURNAL OF MEDICINE

ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ

(2016) Johannes Breyer et al.   UROLOGIA INTERNATIONALIS

Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non–muscle-invasive high-grade bladder cancer

(2016) Niccolo Passoni et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Prognostic Significance of Nestin Expression in pT1 High-Grade Bladder Urothelial Carcinoma Patients Treated with Intravesical BCG

(2015) Volkan Sen et al.   Asian Pacific Journal of Cancer Prevention

Sphingosine-1-phosphate receptor 1 (S1PR1) expression in non-muscle invasive urothelial carcinoma: Association with poor clinical outcome and potential therapeutic target

(2015) Heounjeong Go et al.   EUROPEAN JOURNAL OF CANCER

Immunoprofile-based subgrouping of urothelial bladder carcinomas for survival prediction

(2015) Kyungeun Kim et al.   HUMAN PATHOLOGY

ΔNp63 Expression is a Protective Factor of Progression in Clinical High Grade T1 Bladder Cancer

(2015) Josep M. Gaya et al.   JOURNAL OF UROLOGY

Expression of inflammasome-related genes in bladder cancer and their association with cytokeratin 20 messenger RNA

(2015) Giulia Poli et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer

(2014) Paola Gazzaniga et al.   INTERNATIONAL JOURNAL OF CANCER

Evaluación de la sobreexpresión de proteína HER2 en cáncer vesical no músculo invasivo con énfasis en el grado tumoral y en la recurrencia

(2013) A. Janane et al.   Actas Urologicas Espanolas

Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder

(2013) E Xylinas et al.   BRITISH JOURNAL OF CANCER

Recurrence of high-risk bladder cancer: A population-based analysis

(2013) Karim Chamie et al.   CANCER

p16INK4aoverexpression and p16/Ki-67 dual labeling versus conventional urinary cytology in the evaluation of urothelial carcinoma

(2013) Eric Piaton et al.   CANCER CYTOPATHOLOGY

Introduction and First Clinical Application of a Simplified Immunohistochemical Validation System Confirms Prognostic Impact of KI-67 and CK20 for Stage T1 Urothelial Bladder Carcinoma: Single-Center Analysis of Eight Biomarkers in a Series of Three Hundred Six Patients

(2013) Wolfgang Otto et al.   Clinical Genitourinary Cancer

Predictive value of Sox2 expression in transurethral resection specimens in patients with T1 bladder cancer

(2013) Jun Ruan et al.   MEDICAL ONCOLOGY

Differentiating progressive from nonprogressive T1 bladder cancer by gene expression profiling: Applying RNA-sequencing analysis on archived specimens

(2013) Xuanhui Sharron Lin et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

High Expression of H3K27me3 Is an Independent Predictor of Worse Outcome in Patients with Urothelial Carcinoma of Bladder Treated with Radical Cystectomy

(2013) Jianye Liu et al.   Biomed Research International

Cathepsin E, Maspin, Plk1, and Survivin Are Promising Prognostic Protein Markers for Progression in Non-Muscle Invasive Bladder Cancer

(2012) Niels Fristrup et al.   AMERICAN JOURNAL OF PATHOLOGY

Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer

(2012) Bas W.G. van Rhijn et al.   BJU INTERNATIONAL

Combination of CK20 and Ki-67 Immunostaining Analysis Predicts Recurrence, Progression, and Cancer-Specific Survival in pT1 Urothelial Bladder Cancer

(2012) Simone Bertz et al.   EUROPEAN UROLOGY

Use of Fluorescence In Situ Hybridization to Predict Response to Bacillus Calmette-Guérin Therapy for Bladder Cancer: Results of a Prospective Trial

(2012) Ashish M. Kamat et al.   JOURNAL OF UROLOGY

Urine Markers for Detection and Surveillance of Non–Muscle-Invasive Bladder Cancer

(2011) Derya Tilki et al.   EUROPEAN UROLOGY

Molecular Grade (FGFR3/MIB-1) and EORTC Risk Scores Are Predictive in Primary Non–Muscle-Invasive Bladder Cancer

(2010) Bas W.G. van Rhijn et al.   EUROPEAN UROLOGY

Myopodin Methylation is Associated With Clinical Outcome in Patients With T1G3 Bladder Cancer

(2010) Miguel Alvarez-Múgica et al.   JOURNAL OF UROLOGY

Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients

(2009) M. Lae et al.   ANNALS OF ONCOLOGY

Survivin Expression as a Predictive Marker for Local Control in Patients With High-Risk T1 Bladder Cancer Treated With Transurethral Resection and Radiochemotherapy

(2009) Christian Weiss et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Predictive value of telomerase reverse transcriptase expression in patients with high risk superficial bladder cancer treated with adjuvant BCG immunotherapy

(2009) Ioannis Zachos et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Predictive Value of Combined Immunohistochemical Markers in Patients With pT1 Urothelial Carcinoma at Radical Cystectomy

(2009) Shahrokh F. Shariat et al.   JOURNAL OF UROLOGY

Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model

(2009) Jesus Fernandez-Gomez et al.   JOURNAL OF UROLOGY

Bladder cancer

(2009) Donald S Kaufman et al.   LANCET

Prediction of Progression of Non–Muscle-Invasive Bladder Cancer by WHO 1973 and 2004 Grading and by FGFR3 Mutation Status: A Prospective Study

(2008) Maximilian Burger et al.   EUROPEAN UROLOGY

Protein Expression Patterns of Ezrin Are Predictors of Progression in T1G3 Bladder Tumours Treated with Nonmaintenance Bacillus Calmette-Guérin

(2008) Joan Palou et al.   EUROPEAN UROLOGY

Does the Expression of Fascin-1 and Tumor Subclassification Help to Assess the Risk of Recurrence and Progression in T1 Urothelial Urinary Bladder Carcinoma?

(2008) V. Soukup et al.   UROLOGIA INTERNATIONALIS